amphetamine has been researched along with plerixafor in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Alves, A; Calhoun, C; Donaldson, ST; Dunn, C; Kanda, R; Mason, B; Pina, L; Woytowicz, V | 1 |
1 review(s) available for amphetamine and plerixafor
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for amphetamine and plerixafor
| Article | Year |
|---|---|
CXCR4 inhibition with AMD3100 attenuates amphetamine induced locomotor activity in adolescent Long Evans male rats.
Topics: Amphetamine; Animals; Anti-HIV Agents; Benzylamines; Central Nervous System Stimulants; Cyclams; Gene Expression Regulation; Locomotion; Male; Rats; Rats, Long-Evans; Receptors, CXCR4 | 2021 |